Prediction: ASML Could Be One of the Best Semiconductor Stocks of 2026

ASML reported a standout 2025 with Q4 bookings up to €13.15bn (vs €7bn in Q4 2024), full-year net sales of €32.6bn (+15.5%), net income of €9.6bn (+27%) and EPS up 28%; EUV machine sales grew 39% to €11.6bn. Margins remain robust (gross 52%, operating 35%), net cash rose to $15.17bn while total debt fell 21.5% to $3.18bn, free cash flow was €12.42bn (+29%) and operating cash flow €12.93bn (+24.5%). Management announced a €12bn share buyback through Dec. 31, 2028 and guided 2026 net sales of €34–39bn with gross margin of 51–53%, reinforcing ASML’s monopoly position in EUV lithography and positive investor outlook.

Analysis

Market structure: ASML's Q4 bookings surge (13.15€B vs 7€B) and 12€B buyback materially shift semiconductor capital-equipment economics — ASML (EUV) is the high-margin bottleneck supplier while legacy DUV vendors face demand compression (DUV sales down 6%). Pricing power should remain strong: 51–53% gross margin guidance and >€12B FCF imply ability to extract premium pricing and accelerate buybacks, tightening free float by potentially several percent of market cap over 24–36 months.

Risk assessment: Key tail risks are regulatory export restrictions to China (loss of ~X% of addressable market within 12–24 months), a major supplier failure (Zeiss/laser supplier disruption delaying deliveries by >6 months), or a sudden semiconductor capex pull-forward reversal that cuts bookings >30% YoY. Near-term (days–weeks) expect volatility around earnings and buyback execution details; medium-term (quarters) hinge on quarterly bookings and delivery cadence; long-term (years) depends on geopolitical export policy and competitor technology emergence.

Trade implications: Base case: long ASML (ASML) with size 2–5% of equity risk budget, funded by reducing general semiconductor beta exposure. Options: buy 12–18 month LEAP call spreads to capture secular EUV adoption while capping premium; sell 3–6 month cash-secured puts 10% OTM to collect yield if comfortable allocating at lower prices. Sector rotation: favor semiconductor equipment and materials suppliers tied to advanced nodes, trim GPU/high-beta semiconductor longs (NVDA) by 1–2% of portfolio to rebalance exposure.

Contrarian angles: Consensus underweights geopolitical/antitrust execution risk and overweights buyback-driven EPS accretion — if export curbs remove >10% of addressable sales, buyback synergistic benefit could be negated and multiple could compress >20%. Conversely, market may be underpricing structural margin upside from service/consumables tied to EUV (recurring revenue), which could lift FCF conversion above €13B and justify a further 10–25% multiple expansion over 12–24 months.

Key Decisions for Investors

• Establish a 2–3% net long position in ASML (ASML) within 2 weeks; scale to 4–5% if next two quarterly bookings average ≥€10B and guidance midpoint ≥€36.5B. Use a 15% stop-loss from entry or hedge with 12–18 month puts 20% OTM if regulatory news increases volatility.
• Deploy options: buy a 12–18 month LEAP call spread (e.g., Jan 2027 50–60% OTM debit vertical) sized for 1–2% notional to capture upside while limiting premium, and concurrently sell 3–6 month 10% OTM cash-secured puts to generate ~3–6% annualized yield on target entry.
• Execute a relative-value hedge: pair long ASML (size 3%) with a short NVDA position at half notional (1.5%) to reduce semiconductor cycle/GPU concentration; unwind the short if NVDA guidance shows GPU-driven capex acceleration within 3 months.
• Reduce broad semiconductor beta (SOXX exposure) by 2% and reallocate that risk to ASML and selected equipment suppliers (optics/laser suppliers) if ASML quarterly bookings stay >€10B for two consecutive quarters; if bookings fall below €8B in any quarter, cut ASML exposure to ≤1% within 30 days.